How to Think About Longevity Interventions — By Looking for Where They Break
Olafur’s Substack
SubscribeSign in
How to Think About Longevity Interventions — By Looking for Where They Break
Olafur Pall Olafsson<br>Mar 06, 2026
Share
In longevity science, interventions often gain attention long before they deserve confidence.<br>Typically what happens is something like this: a new biological mechanism is identified that appears relevant to aging. A rodent study shows benefit, perhaps even an increase in lifespan. A biomarker shifts in what looks like the right direction. Gradually a narrative forms around the idea that this new intervention might improve longevity.<br>Many people then become enthusiastic and begin acting on it.<br>What is usually missing is not intelligence or data, but a disciplined attempt to follow the entire causal chain from intervention to meaningful human effect, and to ask where that chain is most likely to fracture.<br>One of the difficulties in studying aging is that it is not a process that unfolds over weeks. Aging reflects gradual changes in damage accumulation, repair capacity, and system regulation that develop over decades (I discussed the underlying biology of aging in more detail here). Any intervention that genuinely modifies that trajectory will tend to produce effects that are subtle and slow.<br>This creates a predictable bias. Interventions that produce noticeable short-term effects, such as improvements in energy, recovery, inflammation, or metabolic markers, often act on adaptive physiology rather than on the underlying processes that determine lifespan. Such interventions may still be useful. But they are not necessarily modifying aging itself.<br>At the same time, both harms and benefits in aging biology can take years to become visible. An intervention that slightly reduces structural damage accumulation may show no detectable benefit in the short term, while another that provokes strong physiological responses may appear impressive long before long-term costs become apparent.<br>This becomes particularly problematic because many interventions are evaluated using short-term markers: biomarkers changes, physiological responses, or subjective improvements in how someone feels. These signals are often treated as evidence that something works, or that it does not.<br>But unless a biomarker is known to be causally connected to the aging process, its short-term movement tells us very little about long-term outcomes. A change in a marker is only meaningful when we understand how that marker actually participates in the biological processes that drive aging.<br>Rather than starting with theory alone, it is often more useful to examine specific interventions and follow them all the way through the biological and translational constraints they must survive.<br>Apigenin: When Mechanistic Logic Collides With Pharmacology
Apigenin attracted attention because it inhibits CD38 in laboratory systems. CD38 degrades NAD⁺, NAD⁺ declines with age, and restoring NAD⁺ has produced metabolic and functional benefits in animal models.<br>The conceptual chain therefore looks straightforward:<br>Ingest apigenin → inhibit CD38 → preserve NAD⁺ → improve aging biology.<br>For this to work in humans, several conditions would have to be met simultaneously. The compound would need to survive digestion and metabolism, reach the systemic circulation in sufficient amounts, enter relevant tissues, accumulate to concentrations capable of inhibiting CD38 inside cells, and maintain that effect over time.<br>This causal chain breaks at exposure.<br>Apigenin is extensively metabolized in the gut and liver. Only small fractions reach the systemic circulation in intact form, and measured plasma concentrations are far below those required to produce meaningful CD38 inhibition in vitro. Dietary intake, even from foods relatively rich in apigenin, is orders of magnitude lower still.<br>The biology itself is not incorrect. If apigenin could be present in sufficiently high concentrations inside cells, it is plausible that CD38 activity could be reduced and NAD⁺ levels preserved.<br>The problem is that the concentrations required to make this mechanism matter are simply not achievable under real-world conditions.<br>This is a recurring pattern in longevity interventions: a compelling mechanistic insight that cannot be translated into viable pharmacology.<br>What would change my view would be direct evidence that achievable human dosing produces sustained increases in tissue NAD⁺ of meaningful magnitude, enough to suggest that the CD38 inhibition pathway is actually operating in vivo.<br>Mesenchymal Stem Cells: When the Intervention Cannot Become the Thing It Claims to Be
Mesenchymal stem cells (MSCs) are frequently described as systemic rejuvenation tools, based on their ability to differentiate into multiple cell types. The implied model is that these cells can function as replacement units for aging tissues.<br>In this view, MSCs are introduced into the body as a...